tiprankstipranks
Trending News
More News >

Acadia Pharmaceuticals price target raised to $23 from $20 at Mizuho

Mizuho raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $23 from $20 and keeps a Neutral rating on the shares. The District Court of Delaware ruled in Acadia’s favor on the patent infringement case against Aurobindo Pharma, the analyst tells investors in a research note. The firm cites the favorable district court ruling for the target raise but still has concerns about Daybue adoption.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue